Onconic Therapeutics (476060) said Tuesday it has completed Phase 3 clinical trials for erosive gastroesophageal reflux disease (GERD) in India and filed a new drug application (NDA) for Jaqbo, its in-house developed drug. The company said additional milestone payments are expected during the approval and launch process, which will contribute to improving this year's revenue and operating profit.
According to market research firm Grand View Research, India's erosive GERD treatment market is estimated at approximately 1.8 trillion won, recognized for its high market potential. With a population of 1.46 billion and changing dietary habits driven by economic growth, the prevalence of related diseases is also increasing. "India has a relatively short review period from new drug application to approval, so Jaqbo's approval process is expected to proceed swiftly," an Onconic Therapeutics official said.
Since its domestic launch in October 2024, Jaqbo has grown rapidly, recording prescription sales of 21.2 billion won in the first quarter of 2026. In April, monthly prescription sales surpassed 8.5 billion won. While expanding its presence in the domestic potassium-competitive acid blocker (P-CAB) market, the company is also pursuing approval for erosive GERD in China together with its local partner Livzon Pharmaceutical. Onconic Therapeutics is also developing additional indications, accelerating its global business expansion.
"Jaqbo has rapidly expanded its presence in the domestic market since its launch, and is now achieving visible development and commercialization results in major overseas markets as well," an Onconic Therapeutics official said. "Based on royalties and milestone payments from the success of our global new drug, we will reinvest in research and development to develop our own new drugs that will become the second and third Jaqbo."
